Page 10 - reflections_newsletter_June8_2022

REFLECTIONS dae mia
Dyslipidaemia Global Newsletter #2
aim ead
Dyslipi

“These results were not a surprise to me but they were for many other experts. They show that in most cases statin intoleranceDyisslipi
over-estimated and over-diagnosed, and they mean that around 93% of patients on statin therapy can be treated effectively, with
very good tolerability and without any safety issues.”

“Our findings mean that we should evaluate patients’ symptoms very carefully, firstly to see whether symptoms are indeed caused
by statins, and secondly, to evaluate whether it might be patients’ perceptions that statins are harmful – so called nocebo or
drucebo effect – which could be responsible for more than 50% of all symptoms, rather than the drug itself.”
Prof. Maciej Banach, Medical University of Lodz, Poland
Quote taken from https://www.escardio.org/The-ESC/Press-Office/Press-releases/Statin-intolerance-is-over-estimated-
and-over-diagnosed

CLICK HERE
FOR THE LINK TO FULL ARTICLE

ADDITIONAL ARTICLES OF INTEREST

1. The year in cardiovascular medicine 2021: Dyslipidaemia. Tokgozoglu L, et al. Eur Heart J. 2022 Feb 22;43(8):807-817.

2. Lipid measurements in the management of cardiovascular diseases: Practical recommendations a scientific
statement from the national lipid association writing group. Wilson PWF, et al. J Clin Lipidol. 2021 Sep-
Oct;15(5):629-648.

3. Lipid-lowering and anti-thrombotic therapy in patients with peripheral arterial disease: European Atherosclerosis
Society/European Society of Vascular Medicine Joint Statement. Belch JJF, et al. Atherosclerosis. 2021 Dec;338:55-63.

4. Fixed-dose combination therapies with and without aspirin for primary prevention of cardiovascular disease: An
individual participant data meta-analysis. Lancet. 2021;398(10306):1133-1146.

5. ALERT-LDL: Adherence to guidelines in the treatment of patients with dyslipidemia. Intern Emerg Med.
2022;17(2):387-395.

6. Association of apolipoprotein b-containing lipoproteins and risk of myocardial infarction in individuals with and
without atherosclerosis: Distinguishing between particle concentration, type, and content. Marston NA, et al. JAMA
Cardiol. 2022 Mar 1;7(3):250-256.

7. Independent association of lipoprotein(a) and coronary artery calcification with atherosclerotic cardiovascular risk.
Mehta A, et al. J Am Coll Cardiol. 2022 Mar 1;79(8):757-768.

8. Assessment of coronary artery calcium scoring to guide statin therapy allocation according to risk-enhancing
factors: The multi-ethnic study of atherosclerosis. Patel J, et al. JAMA Cardiol. 2021 Oct 1;6(10):1161-1170.

9. Remnant cholesterol predicts cardiovascular disease beyond LDL and ApoB: A primary prevention study. Quispe R,
et al. Eur Heart J. 2021 Nov 7;42(42):4324-4332.

10. Discordance between standard equations for determination of LDL cholesterol in patients with atherosclerosis.
Sajja A, et al. J Am Coll Cardiol. 2022 Feb 15;79(6):530-541.

11. Key questions about familial hypercholesterolemia: JACC review topic of the week. Sniderman AD, et al. J Am
Coll Cardiol. 2022 Mar 15;79(10):1023-1031.

TABLE OF CONTENTS Learn more at: www.serviercardiomedicalhub.com